[Active immunization against serogroup B Neisseria meningitidis].
Serogroup B Neisseria meningitidis causes high morbidity and mortality rates over the world. This article reviews the current vaccination strategies against this microorganism, including vaccines already tested on a large scale, particularly those based on class 1 outer membrane proteins, and vaccines in different stages of development. The latter involve several approaches, such as modification of the polysaccharide capsule composition or conjugation with proteins, and the use of recombinant DNA techniques to obtain vaccines that express the prevalent sero-subtypes in a particular geographical area. The challenges that have emerged with the sequencing of the meningococcus B genome are also addressed.
Consejería de Sanidad. Murcia. España. josea.navarro2@carm.es
José Antonio
JA
Navarro-Alonso
D000907:Antibodies, Bacterial / Q000096:biosynthesis / Q000276:immunology; D000942:Antigens, Bacterial / Q000276:immunology; D016667:Bacterial Capsules; D001425:Bacterial Outer Membrane Proteins / Q000276:immunology; D002986:Clinical Trials as Topic; D003429:Cross Reactions; D006801:Humans; D007075:Immunoglobulin M / Q000096:biosynthesis; D008585:Meningitis, Meningococcal / Q000276:immunology / Q000382:microbiology / Q000517:prevention & control*; D022401:Meningococcal Vaccines / Q000276:immunology*; D038541:Neisseria meningitidis, Serogroup B / Q000276:immunology*; D011135:Polysaccharides, Bacterial / Q000276:immunology; D013045:Species Specificity; D014611:Vaccination; D018074:Vaccines, Conjugate / Q000276:immunology; D014614:Vaccines, Synthetic / Q000276:immunology
D000907:Antibodies, Bacterial; D000942:Antigens, Bacterial; D001425:Bacterial Outer Membrane Proteins; D007075:Immunoglobulin M; D022401:Meningococcal Vaccines; D011135:Polysaccharides, Bacterial; D018074:Vaccines, Conjugate; D014614:Vaccines, Synthetic; C039455:capsular polysaccharide, meningococcal group B